Answers are grounded in this paper and cite their sources.
Examines anti-cancer efficacy of TOP1/PARP1 dual-target inhibitors, suggesting potential for overcoming treatment resistance.
represents a promising TOP1/PARP1 inhibitor for overcoming resistance to conventional DNA-damaging chemotherapies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: